Uncategorized

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target CNS disorders, including certain diseases that may benefit

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid improved transduction in multiple CNS regions and cell types in non-human primates with partial

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™  AAV9- and AAV5-derived capsids Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of

CAMBRIDGE, Mass. , May 03, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics , Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Society of

Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy CAMBRIDGE, Mass. , March 22, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and

License option agreement with Novartis for target-specific access to TRACER™  next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to Voyager’s novel TRACER AAV capsids for potential use with three CNS targets plus options to access

CAMBRIDGE, Mass. , Feb. 10, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor

CAMBRIDGE, Mass. , Feb. 10, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor

Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing